HomeCONGRESS

CONGRESS

View Category
Day 2

RIBS V: Pharmacological balloon vs second-generation drug-eluting stent in the treatment of BMS restenosis

The ideal therapy for treating in-stent restenosis continues to be debated . The pharmacological balloons showed good...
solaci -
Learn More
Day 2

LEVANT 2: Initial results from the new drug eluting balloon for femoropopliteal lesions

This prospective multicenter study randomized 476 patients 2:1 to paclitaxel eluting balloon versus conventional balloon for femoropopliteal...
solaci -
Learn More
Day 2

Exclusive Interview with Dr. Henrique Ribeiro on his article: coronary obstruction after TAVI

Recentemente uma revisão e metanálise sobre obstrução coronária após o implante de TAVI foi publicada na revista...
solaci -
Learn More
Day 2

HeartFlowNXT: Using noninvasive FFR shows promising results

The use of fractional flow reserve (FFR) is useful to determine the significance of coronary lesions. The...
solaci -
Learn More
Day 3

ARCTIC-INTERRUPTION: 1 years versus 2 years of double anti-platelet

This study randomized 1259 patients to receive one year versus 2 years of double anti anti-platelet after...
solaci -
Learn More
Miscellaneus

Non-cardiac surgery and coronary DES

Ajay Kirtane 2011-08-04
solaci -
Learn More
Miscellaneus

Global adoption of the transradial approach. The end of myths

Pablo Vázquez 2011-08-04
solaci -
Learn More
Day 1

SORT OUT VI: Biolimus eluting stent versus zotarolimus-eluting stent; similar results

Few studies have compared head to head the 2nd generation drug eluting stents. This study randomized 1:1...
solaci -
Learn More